Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997

Jihad Bishara; Silvio Pitlik; Zmira Samra; Itzhak Levy; Mical Paul; Leonard Leibovici

doi:10.3201/eid0909.020666

Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997

Emerg Infect Dis. 2003 Sep;9(9):1168-9. doi: 10.3201/eid0909.020666.

Authors

Jihad Bishara¹, Silvio Pitlik, Zmira Samra, Itzhak Levy, Mical Paul, Leonard Leibovici

Affiliation

¹ Department of Internal Medicine C, Rabin Medical Center, Beilinson Campus, Petach-Tikvah, Israel. [email protected]

Abstract

Among bloodstream methicillin-resistant Staphylococcus aureus (MRSA) isolates from adult patients in a single hospital, susceptibility to co-trimoxazole increased progressively from 31% in 1988 to 92% in 1997 (p<0.0001). If also observed in other institutions, these findings should encourage the performance of a clinical trial of sufficient size to compare co-trimoxazole to vancomycin in treating MRSA infections.

MeSH terms

Adult
Anti-Bacterial Agents / therapeutic use*
Cross Infection / drug therapy*
Cross Infection / epidemiology
Humans
Israel / epidemiology
Methicillin Resistance*
Microbial Sensitivity Tests
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / epidemiology
Staphylococcus aureus / drug effects*
Staphylococcus aureus / isolation & purification
Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology*

Substances

Anti-Bacterial Agents
Trimethoprim, Sulfamethoxazole Drug Combination